239 327

Cited 15 times in

The Role of 18 F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy

DC FieldValueLanguage
dc.contributor.author강원준-
dc.contributor.author김영태-
dc.contributor.author김용배-
dc.contributor.author김현정-
dc.contributor.author윤미진-
dc.contributor.author이재훈-
dc.contributor.author이종두-
dc.contributor.author조응혁-
dc.date.accessioned2015-01-06T17:22:32Z-
dc.date.available2015-01-06T17:22:32Z-
dc.date.issued2014-
dc.identifier.issn1869-3474-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/99861-
dc.description.abstractPURPOSE: To determine whether persisting cervical fluorodeoxyglucose (FDG) uptake after concurrent chemoradiotherapy (CCRT) for cervical cancer can reflect residual malignancy. METHODS: F-FDG PET/CT was performed before and after CCRT in 136 patients with cervical cancer. The maximum and mean standardized uptake values (SUVmax and SUVmean) were recorded from PET/CT scans performed pre- and post-treatment. SUVs were correlated with treatment response after CCRT. Final treatment response was determined by MRI and further follow-up PET/CT. One hundred four of 136 patients underwent pelvic MRI, and 32 of 136 patients underwent further follow-up PET/CT. Patients were classified into two categories: patients with residual tumor or patients without residual tumor (complete responder). Pre- and post-treatment serum squamous cell carcinoma antigen (SCC) levels were also recorded for comparison. The optimal cutoff value of SUVmax for predicting residual cervical tumor was determined using receiver-operating characteristic (ROC) analysis. RESULTS: Of 136 patients, 124 showed complete response on further follow-up studies and 12 were confirmed to have residual tumor. The post-treatment SUVmax and pre-/post-treatment SUVmean of complete responders were significantly lower than those of patients with residual tumor: 2.5 ± 0.8 and 7.2 ± 4.2/1.9 ± 0.7 for complete responders and 5.7 ± 2.6 and 12.8 ± 6.9/3.7 ± 0.7 for patients with residual tumor (p < 0.05). The pre-treatment SUVmax and pre-/post-treatment serum SCC levels of the complete responders tended to be lower than those of patients with residual tumor, but this did not have statistical significance. Using ROC analysis, an optimal cutoff SUVmax of 4.0 on the post-treatment PET/CT yielded a sensitivity, specificity, positive predictive value, and negative predictive value of 92 %, 94 %, 61 %, and 99 %, respectively (p < 0.001). CONCLUSIONS: Persistent cervical FDG uptake in(18)F-FDG PET/CT after CCRT for cervical cancer may be caused by residual tumor or post-therapy inflamma-
dc.description.statementOfResponsibilityopen-
dc.format.extent130~136-
dc.relation.isPartOfNUCLEAR MEDICINE AND MOLECULAR IMAGING-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleThe Role of 18 F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학)-
dc.contributor.googleauthorJiyoun Choi-
dc.contributor.googleauthorHyun Jeong Kim-
dc.contributor.googleauthorYong Hyu Jeong-
dc.contributor.googleauthorJae-Hoon Lee-
dc.contributor.googleauthorArthur Cho-
dc.contributor.googleauthorMijin Yun-
dc.contributor.googleauthorJong Doo Lee-
dc.contributor.googleauthorYong Bae Kim-
dc.contributor.googleauthorYoung Tae Kim-
dc.contributor.googleauthorWon Jun Kang-
dc.identifier.doi10.1007/s13139-013-0248-y-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02550-
dc.contributor.localIdA00062-
dc.contributor.localIdA00729-
dc.contributor.localIdA03138-
dc.contributor.localIdA03887-
dc.contributor.localIdA00744-
dc.contributor.localIdA03093-
dc.contributor.localIdA01129-
dc.contributor.localIdA05554-
dc.relation.journalcodeJ02382-
dc.identifier.eissn1869-3482-
dc.identifier.pmid24900153-
dc.subject.keywordCCRT-
dc.subject.keywordCervical cancer-
dc.subject.keywordPET/CT-
dc.subject.keywordTreatment response-
dc.contributor.alternativeNameKang, Won Jun-
dc.contributor.alternativeNameKim, Young Tae-
dc.contributor.alternativeNameKim, Yong Bae-
dc.contributor.alternativeNameKim, Hyun Jeong-
dc.contributor.alternativeNameYun, Mi Jin-
dc.contributor.alternativeNameLee, Jae Hoon-
dc.contributor.alternativeNameLee, Jong Doo-
dc.contributor.alternativeNameCho, Arthur Eung Hyuck-
dc.contributor.affiliatedAuthorYun, Mi Jin-
dc.contributor.affiliatedAuthorKang, Won Jun-
dc.contributor.affiliatedAuthorKim, Young Tae-
dc.contributor.affiliatedAuthorLee, Jong Doo-
dc.contributor.affiliatedAuthorCho, Arthur Eung Hyuck-
dc.contributor.affiliatedAuthorKim, Yong Bae-
dc.contributor.affiliatedAuthorLee, Jae Hoon-
dc.contributor.affiliatedAuthorKim, Hyun Jeong-
dc.contributor.affiliatedAuthorJeong, Yong Hyu-
dc.citation.volume48-
dc.citation.number2-
dc.citation.startPage130-
dc.citation.endPage136-
dc.identifier.bibliographicCitationNUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol.48(2) : 130-136, 2014-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.